ArticleHuman vaccines & immunotherapeutics2025
Safety Surveillance for Hepatitis A Vaccine using the U.S. Vaccine Adverse Event Reporting System (VAERS) database.
Article in Human vaccines & immunotherapeutics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Real‑world pharmacovigilance of rituximab‑associated adverse reactions in children and adolescents: Disproportionality signal detection and time‑to‑onset pattern characterization using the FAERS database.Human vaccines & immunotherapeutics · 2026Article
- Integrating non-neonatal tetanus vaccination into an emergency department rabies PEP clinic: Real-world workload, documentation gaps, and VAERS-informed observation priorities.Human vaccines & immunotherapeutics · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hepatitis A virus (HAV) infection remains a significant global public health concern. Vaccination is the key to preventing HAV, and its efficacy has been confirmed. While most reported adverse events following hepatitis A vaccination are mild, recent years have seen limited research on its safety based on real-world pharmacovigilance analysis. We collected all the reports in the VAERS database from 1995 to 2024 related to the Hepatitis A Vaccines, and the incidence of HAV infection from GBD 2021. A disproportionality analysis using the reporting odds ratio (ROR) with a 95% confidence interval was performed. 45,645 individual case safety reports referring to Hepatitis A Vaccine have been recorded in VAERS until 2024, which corresponds to 151,800 drug-reaction pairs. The most frequently reported were non-serious: pyrexia (5,951 reports), Injection Site Erythema (5,071), etc. Pallor, injection site induration, injection site erythema, and so on, show a statistically significant ROR. There are some differences between the studied detected signals and the package insert information. The analysis of adverse event signals based on the VAERS database provides relatively reliable results. It is recommended that vaccine manufacturers further evaluate these newly identified signals and update the package inserts accordingly. Additionally, enhanced monitoring of adverse events during vaccine administration is necessary.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.